Oncology
1 drug is in development for HCC - Hepatocellular Carcinoma.
- Companies
- 1
- Clinical trials
- 6
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the HCC - Hepatocellular Carcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| decoy20 | Indaptus Therapeutics, Inc. (INDP) |
About this indication
HCC - Hepatocellular Carcinoma context
Oncology·MeSH: Carcinoma, Hepatocellular (D006528)
Narrower concept of MeSH descriptor Hepatocellular Carcinoma
Prevalence
12.0 / 100K
Incidence
8.6 / 100K/yr
Frequently asked questions
How many drugs are in development for HCC - Hepatocellular Carcinoma?
BioSniper tracks 1 drug in development for HCC - Hepatocellular Carcinoma across 1 company.
How many clinical trials target HCC - Hepatocellular Carcinoma?
There are 6 clinical trials targeting HCC - Hepatocellular Carcinoma tracked by BioSniper.
What is the prevalence of HCC - Hepatocellular Carcinoma?
The estimated prevalence of HCC - Hepatocellular Carcinoma is approximately 12.0 per 100,000 population.